doi: 10.1021/jm00101a023.
A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase
Affiliations
- PMID: 1447744
- DOI: 10.1021/jm00101a023
Item in Clipboard
A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase
J Med Chem.
.
Abstract
N-[4-[2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid (15), prepared in five steps from 2-pivaloyl-7-deazaguanine, has been found to be an antitumor agent with its primary site of action at thymidylate synthase rather than purine synthesis. This compound appears to be a promising candidate for clinical evaluation.
Similar articles
-
Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.J Med Chem. 2005 Nov 17;48(23):7215-22. doi: 10.1021/jm058234m. J Med Chem. 2005. PMID: 16279780
-
Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and as potential antitumor agents.J Med Chem. 2003 Feb 13;46(4):591-600. doi: 10.1021/jm0203534. J Med Chem. 2003. PMID: 12570380
-
Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1).J Med Chem. 2006 Feb 9;49(3):1055-65. doi: 10.1021/jm058276a. J Med Chem. 2006. PMID: 16451071 Free PMC article.
-
Pemetrexed disodium (Eli Lilly).Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22. Curr Opin Investig Drugs. 2001. PMID: 11763166 Review.
-
Pemetrexed: current development and future directions in thoracic cancers.Suppl Tumori. 2002 Jul-Aug;1(4):S11-2. Suppl Tumori. 2002. PMID: 12415805 Review. No abstract available.
Cited by
-
Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.Clin Transl Oncol. 2016 Jan;18(1):107-12. doi: 10.1007/s12094-015-1359-y. Epub 2015 Jul 29. Clin Transl Oncol. 2016. PMID: 26220094 Clinical Trial.
-
Folic Acid Antimetabolites (Antifolates): A Brief Review on Synthetic Strategies and Application Opportunities.Molecules. 2022 Sep 22;27(19):6229. doi: 10.3390/molecules27196229. Molecules. 2022. PMID: 36234766 Free PMC article. Review.
-
Pemetrexed Hinders Translation Inhibition upon Low Glucose in Non-Small Cell Lung Cancer Cells.Metabolites. 2021 Mar 26;11(4):198. doi: 10.3390/metabo11040198. Metabolites. 2021. PMID: 33810430 Free PMC article.
-
Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.J Med Chem. 2008 Jan 10;51(1):68-76. doi: 10.1021/jm701052u. Epub 2007 Dec 12. J Med Chem. 2008. PMID: 18072727 Free PMC article.
-
Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.Bioorg Med Chem. 2011 Jun 1;19(11):3585-94. doi: 10.1016/j.bmc.2011.03.067. Epub 2011 Apr 9. Bioorg Med Chem. 2011. PMID: 21550809 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Chemical Information
Medical